BibTeX
CSL-JSON
MLA
Harvard
Pharmaceutical Approval Update
release_di6qn3lqgzhslfy2xgegh4msvq
by
Michele B Kaufman
Published
in P & T : a peer-reviewed journal for formulary management.
2016 Volume 41, Issue 10, p617-639
Abstract
Obeticholic acid (Ocaliva) for primary biliary cholangitis; sofosbuvir 400 mg/velpatasvir 100 mg (Epclusa) for chronic hepatitis C virus infection; and daclizumab (Zinbryta) for relapsing multiple sclerosis.
In text/plain format
Archived Files and Locations
application/pdf 558.6 kB
file_hnn6rcjvrnfndaisxntuortiii
|
europepmc.org (repository) web.archive.org (webarchive) |
Read Archived PDF
Preserved and Accessible
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
access all versions, variants, and formats of this works (eg, pre-prints)
Cite This
Lookup Links